Information Provided By:
Fly News Breaks for May 29, 2019
FGEN
May 29, 2019 | 06:25 EDT
Goldman Sachs analyst Paul Choi assumed coverage of FibroGen with a Neutral rating and $45 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $56 price target. Following the recent Phase 3 MACE safety results for roxadustat, the analyst sees the shares as range-bound pending further clarity from the FDA.
News For FGEN From the Last 2 Days
There are no results for your query FGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.